Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Aravind

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Diabetes & Metabolic Syndrome|May 20, 2022
Role and importance of high fiber in diabetes management in IndiaBanshi Saboo, Anoop Misra, Sanjay Kalra, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 1, 2022
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix InsulinS R Aravind, Kiran P Singh, Liliia Mogylnytska, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 14, 2022
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)S R Aravind, Kiran P Singh, Grace Aquitania, et al.
Diabetes & Metabolic Syndrome|January 16, 2019
Recommendations for in-clinic PoCT for diabetes management in IndiaBanshi Saboo, Shaukat Sadikot, K M Prasanna Kumar, et al.
Current Medical Research and Opinion|June 29, 2012
Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic studyS R Aravind, Shaiful Bahari Ismail, R Balamurugan, et al.
Diabetes & Metabolic Syndrome|July 21, 2022
Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitusAbdul Hamid Zargar, Sanjay Kalra, Prasanna Kumar K M, et al.
International Journal of Diabetes in Developing Countries|June 26, 2023
Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approachAshok Kumar Das, Banshi Saboo, Rajeev Chawla, et al.
Diabetes & Metabolic Syndrome|March 7, 2025
Ahmedabad declaration: A framework to combat growing epidemic of young-onset type 2 diabetes in AsiaRakesh M Parikh, Banshi Saboo, Anoop Misra, et al.
Diabetes & Metabolic Syndrome|September 10, 2014
Consensus guidelines for glycemic monitoring in type 1/type 2 & GDMJothydev Kesavadev, Shaukat Sadikot, Subhash Wangnoo, et al.
Current Medical Research and Opinion|April 22, 2011
Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational studyS R Aravind, Khaled Al Tayeb, Shaiful Bahari Ismail, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Diabetes & Metabolic Syndrome|May 20, 2022
Role and importance of high fiber in diabetes management in IndiaBanshi Saboo, Anoop Misra, Sanjay Kalra, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 1, 2022
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix InsulinS R Aravind, Kiran P Singh, Liliia Mogylnytska, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 14, 2022
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)S R Aravind, Kiran P Singh, Grace Aquitania, et al.
Diabetes & Metabolic Syndrome|January 16, 2019
Recommendations for in-clinic PoCT for diabetes management in IndiaBanshi Saboo, Shaukat Sadikot, K M Prasanna Kumar, et al.
Current Medical Research and Opinion|June 29, 2012
Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic studyS R Aravind, Shaiful Bahari Ismail, R Balamurugan, et al.
Diabetes & Metabolic Syndrome|July 21, 2022
Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitusAbdul Hamid Zargar, Sanjay Kalra, Prasanna Kumar K M, et al.
International Journal of Diabetes in Developing Countries|June 26, 2023
Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approachAshok Kumar Das, Banshi Saboo, Rajeev Chawla, et al.
Diabetes & Metabolic Syndrome|March 7, 2025
Ahmedabad declaration: A framework to combat growing epidemic of young-onset type 2 diabetes in AsiaRakesh M Parikh, Banshi Saboo, Anoop Misra, et al.
Diabetes & Metabolic Syndrome|September 10, 2014
Consensus guidelines for glycemic monitoring in type 1/type 2 & GDMJothydev Kesavadev, Shaukat Sadikot, Subhash Wangnoo, et al.
Current Medical Research and Opinion|April 22, 2011
Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational studyS R Aravind, Khaled Al Tayeb, Shaiful Bahari Ismail, et al.
Pageof 5